EQRx, Inc.
eqrx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 6, 2023. Its latest SEC filing is a 15-12G from Nov 20, 2023.
10-Q for Q3 FY2023, filed Nov 6, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops medicines for cancer and immune-inflammatory conditions, including small molecules and biologics, for patients around the world.
10-K for FY2022, filed Feb 23, 2023
Who Were Their Customers?
If approved, EQRx plans to tailor its approach by market, combining direct efforts and strategic partnerships; in the United States, it plans to work with payers and health systems to support access.
10-K for FY2022, filed Feb 23, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 6, 2023
−$82.6MView ↗
- ▼ −3% (Loss)
- vs −$85.1M in Q3 FY2022
-
Nov 9, 2023
Revolution Medicines completed its merger with EQRx
EQRx shareholders became entitled to Revolution Medicines shares, and EQRx requested Nasdaq delist its stock and warrants.
Sources
8-K, filed Nov 9, 2023
Pursuant to the Merger Agreement, at the effective time of the First Merger (the “Effective Time”), each share of common stock, par value…View ↗
-
Aug 3, 2023
EQRx terminated its Hansoh and G1 licenses and began winding down its pipeline
The plan included a company-wide headcount reduction and winding down current product programs and research and development.
Sources
8-K, filed Aug 3, 2023
On August 1, 2023, EQRx, Inc. (EQRx) provided written notice to G1 Therapeutics (G1) of its termination of the Exclusive License Agreement…View ↗
-
May 8, 2023
EQRx reset its business and ended licenses for several programs
It prioritized lerociclib, sought commercialization partners for aumolertinib, and planned to move early immune-inflammatory programs to a separate entity.
Sources
8-K, filed May 8, 2023
On May 8, 2023, EQRx, Inc. (EQRx) provided written notice to CStone Pharmaceuticals (CStone) of its termination of the Exclusive License…View ↗
Loading...
